DDInter596 DDInter1760
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.
Doxorubicin {u} (Compound) treats {v} (Disease) liver cancer
liver cancer {u} (Disease) is treated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) downregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) binds {v} (Gene) RALBP1
RALBP1 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is palliated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) downregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) downregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Albendazole
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is downregulated by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Doxorubicin (Compound) treats liver cancer (Disease) and liver cancer (Disease) is treated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) downregulates CDK7 (Gene) and CDK7 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) binds RALBP1 (Gene) and RALBP1 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) downregulates CDK7 (Gene) and CDK7 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) upregulates KIT (Gene) and KIT (Gene) is bound by Dasatinib (Compound) and KIT (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) upregulates STK10 (Gene) and STK10 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Albendazole (Compound) and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Doxorubicin (Compound) upregulates RELB (Gene) and RELB (Gene) is downregulated by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl